Clinical Trials | September 23, 2025
Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer
Importantly, the combination of giredestrant and everolimus was well tolerated
Importantly, the combination of giredestrant and everolimus was well tolerated
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
This predictive technology empowers people with diabetes to take preventive action before complications arise
Merck opens first climate-neutral manufacturing facility in Ireland
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
The lab will facilitate the development of herbal and natural-based solutions
Subscribe To Our Newsletter & Stay Updated
